Amphastar Pharmaceuticals Cash Flow from Investing Activities 2012-2023 | AMPH
Amphastar Pharmaceuticals cash flow from investing activities from 2012 to 2023. Cash flow from investing activities can be defined as the total change in cash resulting from a companies investments
Amphastar Pharmaceuticals Annual Cash Flow Investing
(Millions of US $) |
| 2023 |
$-649 |
| 2022 |
$-33 |
| 2021 |
$-29 |
| 2020 |
$-36 |
| 2019 |
$-51 |
| 2018 |
$-42 |
| 2017 |
$-37 |
| 2016 |
$-40 |
| 2015 |
$-17 |
| 2014 |
$-40 |
| 2013 |
$-18 |
| 2012 |
$-25 |
| 2011 |
$-11 |
| 2009 |
$ |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$2.126B |
$0.644B |
|
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
|
